Abby Hardy, Author at BioTuesdays

Executive Moves

Zenabis names Shai Altman as president and CEO

Shai Altman Zenabis Global (TSX:ZENA) appointed Shai Altman as president and CEO, effective September 1. Mr. Altman will replace interim CEO, Kevin Coft, who will return to his role as Zenabis’ chief...

July 31, 2020

Developments

Marinus gets FDA rare pediatric disease designation for ganaxolone

Marinus Pharmaceuticals (NASDAQ:MRNS) received FDA rare pediatric disease designation for ganaxolone for the treatment of CDKL5 deficiency disorder (CDD). CDD is a rare refractive form of pediatric epilepsy caused by a...

July 31, 2020

Developments

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates and FastPharming manufacturing system were featured on The Hill’s coronavirus report on July 30. The company is developing IBIO-200 and IBIO-201, virus-like...

July 30, 2020

Developments

Titan Pharma and Indegene provide details of new Probuphine co-promotion partnership

Titan Pharmaceuticals’ (NASDAQ:TTNP) CEO, Sunil Bhonsle, and Indegene VP of co-commercialization, Jamie Peck, provided additional information on their recently established Probuphine co-promotion partnership. In an...

July 29, 2020

Developments

Krystal Biotech initiates Phase 3 dystrophic epidermolysis bullosa trial

Krystal Biotech (NASDAQ:KRYS) initiated a Phase 3 clinical trial evaluating beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). DEB is a rare and severe monogenic skin disease with...

July 29, 2020

Developments

Regulus gets FDA orphan drug designation for polycystic kidney disease

Regulus Therapeutics’ (NASDAQ:RGLS) RGLS4236 received FDA orphan drug designation for the treatment of autosomal dominant polycystic kidney disease (ADPKD). ADPKD is caused by mutations in the PKD1 or PKD2 genes, and is...

July 29, 2020

Developments

Nabriva XENLETA gets European approval for community-acquired pneumonia

The EMA approved Nabriva Therapeutics’ (NASDAQ:NBRV) XENLETA for the treatment of community-acquired pneumonia. The approval is based on efficacy data from two Phase 3 clinical trials, both of which established XENLETA...

July 28, 2020

Developments

Protara gets FDA rare pediatric disease designation for lymphatic malformation

Protara Therapeutics’ (NASDAQ:TARA) TARA-002 received FDA rare pediatric disease designation for the treatment of lymphatic malformation. Lymphatic malformations are rare, typically congenital and result in the failure...

July 28, 2020

Developments

Celsion randomizes first patients in Phase 1/2 ovarian cancer study

Celsion (NASDAQ:CLSN) randomized the first two patients in the Phase 2 portion of its Phase 1/2 study evaluating GEN-1 for the treatment of advanced ovarian cancer. GEN-1 is an interleukin-12 DNA plasmid vector...

July 27, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Author - Abby Hardy

Zenabis names Shai Altman as president and CEO

Marinus gets FDA rare pediatric disease designation for ganaxolone

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

Titan Pharma and Indegene provide details of new Probuphine co-promotion partnership

Krystal Biotech initiates Phase 3 dystrophic epidermolysis bullosa trial

Regulus gets FDA orphan drug designation for polycystic kidney disease

Nabriva XENLETA gets European approval for community-acquired pneumonia

Protara gets FDA rare pediatric disease designation for lymphatic malformation

Celsion randomizes first patients in Phase 1/2 ovarian cancer study

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

General

More